A Phase 2 interventional study of Oral insulin in Type 2 Diabetes Treated With Insulin, sponsored by Roger New. Completed at 1 site in United Kingdom. Open to participants aged 35 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-02-06.
Sponsored by Roger New · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing insulin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 1 of them phase 3. Insulin · Diabetes Mellitus, Type 2.
Among the 54 studies testing insulin in Diabetes Mellitus, Type 2, this one is the 15th largest by enrollment, is one of 2 that started in 2018, is one of 11 in phase 2, and was the 51st registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing insulin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 55–80
Ohio State University · Sites in United States
Ages 18+ · Women only
Emory University · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 35 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 8 · Phase 4 20
First in 1995; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 153 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 60 across the 54 interventional studies. Of the 44 that completed or were terminated, 19 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Roger New as lead sponsor.
Roger New has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
3 of the studies testing insulin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06251635Centre for Addiction and Mental HealthEffects of Antipsychotics on Brain Insulin Action in Females | 2026-12-31 |
| NCT06699810Emory UniversityModeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity | 2027-01 |
| NCT07293715Ohio State UniversityPermissive Versus Strict Intrapartum Glucose Management in Type 1 and Type 2 Diabetes (PRISM) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing insulin in Diabetes Mellitus, Type 2, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study was to compare the pharmacodynamic properties of different doses of regular human insulin administered in capsule form twice daily in a randomised twelve-week open-label trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of diabetic ketoacidosis requiring hospitalization within 6 months prior to enrolment, case of proliferative retinopathy or advanced neuropathy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Capsule containing 75iu recombinant human insulin administered two times per day
Drug: Oral insulin
Capsule containing 150iu recombinant human insulin administered two times per day
Drug: Oral insulin
Capsule containing 300iu recombinant human insulin administered two times per day
Drug: Oral insulin
Capsule administered by mouth with a glass of water two times per day, once before breakfast and once before supper
Change in HbA1c
Change in HbA1c Relative to Baseline at Start of Study
Time frame: 12 weeks
Change in Fasting Plasma Glucose
Change in Fasting Plasma Glucose Relative to Baseline at Start of Study
Time frame: 12 weeks
Change in Post-Prandial Glucose
Change in Post-Prandial Glucose Relative to Baseline at Start of study
Time frame: 12 weeks
Changes in Triglycerides
Change in Triglycerides Relative to Baseline at Start of Study
Time frame: 12 weeks
204 patients were assessed for eligibility - 51 did not meet the inclusion criteria. Recruitment was conducted in hospital clinics and commenced one month before the start of study in October 2018
| Milestone | 75iu | 150iu | 300iu |
|---|---|---|---|
| Started | 51 | 50 | 52 |
| Completed | 33 | 29 | 38 |
| Not completed | 18 | 21 | 14 |
| Withdrew: Withdrawal by subject | 1 | 6 | 5 |
| Withdrew: Uncontrolled hyperglycaemia | 1 | 2 | 2 |
| Withdrew: Starting hba1c below 7% | 0 | 1 | 1 |
| Withdrew: No data from central lab (protocol violation) | 14 | 9 | 4 |
| Withdrew: Did not take medication | 2 | 3 | 2 |
Change in HbA1c Relative to Baseline at Start of Study
| % of glycated haemoglobin | 75iu | 150iu | 300iu |
|---|---|---|---|
| Change in HbA1c | -0.20 ± 1.06 | -0.53 ± 1.04 | -0.31 ± 1.04 |
Change in Fasting Plasma Glucose Relative to Baseline at Start of Study
| mg/dL | 75iu | 150iu | 300iu |
|---|---|---|---|
| Change in Fasting Plasma Glucose | -14.8 ± 53.6 | -18.8 ± 39.8 | -2.7 ± 60.09 |
Change in Post-Prandial Glucose Relative to Baseline at Start of study
| mg/dL | 75iu | 150iu | 300iu |
|---|---|---|---|
| Change in Post-Prandial Glucose | -17.4 ± 83.74 | -21.0 ± 86.4 | -31.0 ± 97.7 |
Change in Triglycerides Relative to Baseline at Start of Study
| mg/dL | 75iu | 150iu | 300iu |
|---|---|---|---|
| Changes in Triglycerides | -7.06 ± 10.23 | -22.13 ± 11.02 | 20.56 ± 9.61 |
Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 75iu | 0/33 (0%) | 0/33 (0%) | 0/33 (0%) |
| 150iu | 0/29 (0%) | 0/29 (0%) | 0/29 (0%) |
| 300iu | 0/38 (0%) | 0/38 (0%) | 0/38 (0%) |
Baseline Analysis Population is the number of patients who completed the study according to protocol
| Age, Categorical(Participants) | 75iu | 150iu | 300iu | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 33 | 29 | 38 | 100 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Customized(years) | 75iu | 150iu | 300iu | Total |
|---|---|---|---|---|
| Mean | 48.8 ± 6.4 | 46.6 ± 6.3 | 49.7 ± 7.1 | 48.5 ± 6.7 |
| Sex: Female, Male(Participants) | 75iu | 150iu | 300iu | Total |
|---|---|---|---|---|
| Female | 20 | 16 | 16 | 52 |
| Male | 13 | 13 | 22 | 48 |
| Ethnicity (NIH/OMB)(Participants) | 75iu | 150iu | 300iu | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 33 | 29 | 38 | 100 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 75iu | 150iu | 300iu | Total |
|---|---|---|---|---|
| India | 33 | 29 | 38 | 100 |
| HbA1c (%)(%) | 75iu | 150iu | 300iu | Total |
|---|---|---|---|---|
| Mean | 8.27 ± 0.66 | 8.13 ± 0.65 | 7.93 ± 0.61 | 8.1 ± 0.65 |
| Body weight (kg)(kg) | 75iu | 150iu | 300iu | Total |
|---|---|---|---|---|
| Mean | 63.9 ± 8.3 | 66.1 ± 8.8 | 66.9 ± 12.5 | 65.7 ± 10.2 |
| BMI (kg/m2)(kg/m2) | 75iu | 150iu | 300iu | Total |
|---|---|---|---|---|
| Mean | 25.6 ± 3.0 | 25.8 ± 2.7 | 25.7 ± 2.9 | 25.7 ± 2.8 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2018 to primary completion in Jul 2020, 20 months.
Results were first posted in Feb 2025, 4 years 6 months after primary completion.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 20 months is above that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin